Overexpression of IL-9 induced by STAT3 phosphorylation is mediated by miR-155 and miR-21 in chronic lymphocytic leukemia

Chen,Na; Feng,Lili; Qu,Huiting; Lu,Kang; Li,Peipei; Lv,Xiao; Wang,Xin

doi:10.3892/or.2018.6367

Overexpression of IL-9 induced by STAT3 phosphorylation is mediated by miR-155 and miR-21 in chronic lymphocytic leukemia

Authors:
- Na Chen
- Lili Feng
- Huiting Qu
- Kang Lu
- Peipei Li
- Xiao Lv
- Xin Wang
View Affiliations

Affiliations: Department of Hematology, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China
Published online on: April 12, 2018 https://doi.org/10.3892/or.2018.6367
Pages: 3064-3072

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Interleukin‑9 (IL‑9) can function as both a positive and negative regulator of immune response, however the role of IL‑9 in tumor immunity is poorly understood. Chronic lymphocytic leukemia (CLL) is the most common chronic lympho‑proliferative disorder. Twenty CLL patients from 2010 to 2011 were recruited in the study. Expression and phosphorylation of transcription factor STAT3 and differential microRNAs (miRs) in peripheral blood mononuclear cells (PBMCs) from CLL patient samples were analyzed. In a previous study, we found a high level of IL‑9 in CLL patients. Concomitantly, overexpression of pSTAT3, miR‑155, and miR‑21 were observed in PBMCs from CLL patients in the present study. To elucidate whether there was interaction among IL‑9, STAT3, miR‑155, and miR‑21, MEC‑1 cells were used for further study. Our results revealed that there was no detectable IL‑9 in the culture medium of MEC‑1 cells. However, the IL‑9 protein could be detected using western blotting in MEC‑1 cells. Notably, when recombinant human IL‑9 (rIL‑9) was added to the medium of culturing MEC‑1 cells, the expression levels of pSTAT3 and IL‑9 in MEC‑1 cells were increased in a time‑dependent manner, which could be blocked by STAT3 inhibitor. Both miR‑155 and miR‑21 could increase IL‑9 expression, which could also be suppressed by the inhibitor of STAT3. Our data indicated that the existence of the novel ‘extracellular IL‑9/pSTAT3/miR‑155/miR‑21/intracellular IL‑9’ positive feedback system in CLL cells, provides a novel insight in the pathogenesis and possible therapeutic strategy of CLL.

View Figures

View References

1	Negro R, Gobessi S, Longo PG, He Y, Zhang ZY, Laurenti L and Efremov DG: Overexpression of the autoimmunity-associated phosphatase PTPN22 promotes survival of antigen-stimulated CLL cells by selectively activating AKT. Blood. 119:6278–6287. 2012. View Article : Google Scholar : PubMed/NCBI
2	Oi T, Asanuma K, Matsumine A, Matsubara T, Nakamura T, Iino T, Asanuma Y, Goto M, Okuno K, Kakimoto T, et al: STAT3 inhibitor, cucurbitacin I, is a novel therapeutic agent for osteosarcoma. Int J Oncol. 49:2275–2284. 2016. View Article : Google Scholar : PubMed/NCBI
3	Fecteau JF, Messmer D, Zhang S, Cui B, Chen L and Kipps TJ: Impact of oxygen concentration on growth of mesenchymal stromal cells from the marrow of patients with chronic lymphocytic leukemia. Blood. 121:971–974. 2013. View Article : Google Scholar : PubMed/NCBI
4	Rawstron AC, Böttcher S, Letestu R, Villamor N, Fazi C, Kartsios H, de Tute RM, Shingles J, Ritgen M, Moreno C, et al: European Research Initiative in CLL: Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia. 27:142–149. 2013. View Article : Google Scholar : PubMed/NCBI
5	Samuel S, Beljanski V, Van Grevenynghe J, Richards S, Ben Yebdri F, He Z, Nichols C, Belgnaoui SM, Steel C, Goulet ML, et al: BCL-2 inhibitors sensitize therapy-resistant chronic lymphocytic leukemia cells to VSV oncolysis. Mol Ther. 21:1413–1423. 2013. View Article : Google Scholar : PubMed/NCBI
6	Fang C, Zhuang Y, Wang L, Fan L, Wu YJ, Zhang R, Zou ZJ, Zhang LN, Yang S, Xu W, et al: High levels of CD20 expression predict good prognosis in chronic lymphocytic leukemia. Cancer Sci. 104:996–1001. 2013. View Article : Google Scholar : PubMed/NCBI
7	Soroosh P and Doherty TA: Th9 and allergic disease. Immunology. 127:450–458. 2009. View Article : Google Scholar : PubMed/NCBI
8	Tete S, Saggini A, Maccauro G, Rosati M, Conti F, Cianchetti E, Tripodi D, Toniato E, Fulcheri M, Salini V, et al: Interleukin-9 and mast cells. J Biol Regul Homeost Agents. 26:319–326. 2012.PubMed/NCBI
9	Hornakova T, Staerk J, Royer Y, Flex E, Tartaglia M, Constantinescu SN, Knoops L and Renauld JC: Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers. J Biol Chem. 284:6773–6781. 2009. View Article : Google Scholar : PubMed/NCBI
10	Fionda C, Malgarini G, Soriani A, Zingoni A, Cecere F, Iannitto ML, Ricciardi MR, Federico V, Petrucci MT, Santoni A, et al: Inhibition of glycogen synthase kinase-3 increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: Role of STAT3. J Immunol. 190:6662–6672. 2013. View Article : Google Scholar : PubMed/NCBI
11	Chen DL, Wang DS, Wu WJ, Zeng ZL, Luo HY, Qiu MZ, Ren C, Zhang DS, Wang ZQ, Wang FH, et al: Overexpression of paxillin induced by miR-137 suppression promotes tumor progression and metastasis in colorectal cancer. Carcinogenesis. 34:803–811. 2013. View Article : Google Scholar : PubMed/NCBI
12	Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML and Struhl K: STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell. 39:493–506. 2010. View Article : Google Scholar : PubMed/NCBI
13	Nakamura H, Taguchi A, Kawana K, Kawata A, Yoshida M, Fujimoto A, Ogishima J, Sato M, Inoue T, Nishida H, et al: STAT3 activity regulates sensitivity to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cervical cancer cells. Int J Oncol. 49:2155–2162. 2016. View Article : Google Scholar : PubMed/NCBI
14	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
15	Hartman ML and Kilianska ZM: Lipoprotein lipase: A new prognostic factor in chronic lymphocytic leukaemia. Contemp Oncol (Pozn). 16:474–479. 2012.PubMed/NCBI
16	ENCODE Project Consortium, . Myers RM, Stamatoyannopoulos J, Snyder M, Dunham I, Hardison RC, Bernstein BE, Gingeras TR, Kent WJ, Birney E, Wold B, et al: A user's guide to the encyclopedia of DNA elements (ENCODE). PLoS Biol. 9:e10010462011. View Article : Google Scholar : PubMed/NCBI
17	Chen N, Lv X, Li P, Lu K and Wang X: Role of high expression of IL-9 in prognosis of CLL. Int J Clin Exp Pathol. 7:716–721. 2014.PubMed/NCBI
18	Chen N, Lu K, Li P, Lv X and Wang X: Overexpression of IL-9 induced by STAT6 activation promotes the pathogenesis of chronic lymphocytic leukemia. Int J Clin Exp Pathol. 7:2319–2323. 2014.PubMed/NCBI
19	Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, Wei G, Chepelev I and Zhao K: High-resolution profiling of histone methylations in the human genome. Cell. 129:823–837. 2007. View Article : Google Scholar : PubMed/NCBI
20	Chen J, Petrus M, Bryant BR, Nguyen Phuc V, Stamer M, Goldman CK, Bamford R, Morris JC, Janik JE and Waldmann TA: Induction of the IL-9 gene by HTLV-I Tax stimulates the spontaneous proliferation of primary adult T-cell leukemia cells by a paracrine mechanism. Blood. 111:5163–5172. 2008. View Article : Google Scholar : PubMed/NCBI
21	Matsushita K, Arima N, Ohtsubo H, Fujiwara H, Hidaka S, Fukumori J and Tanaka H: Frequent expression of interleukin-9 mRNA and infrequent involvement of interleukin-9 in proliferation of primary adult T-cell leukemia cells and HTLV-I infected T-cell lines. Leuk Res. 21:211–216. 1997. View Article : Google Scholar : PubMed/NCBI
22	Ju W, Zhang M, Jiang JK, Thomas CJ, Oh U, Bryant BR, Chen J, Sato N, Tagaya Y, Morris JC, et al: CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP. Blood. 117:1938–1946. 2011. View Article : Google Scholar : PubMed/NCBI
23	Schuringa JJ, Wierenga AT, Kruijer W and Vellenga E: Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood. 95:3765–3770. 2000.PubMed/NCBI
24	Brender C, Nielsen M, Kaltoft K, Mikkelsen G, Zhang Q, Wasik M, Billestrup N and Odum N: STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma. Blood. 97:1056–1062. 2001. View Article : Google Scholar : PubMed/NCBI
25	Steele AJ, Prentice AG, Cwynarski K, Hoffbrand AV, Hart SM, Lowdell MW, Samuel ER and Wickremasinghe RG: The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: Potential for reversal of cytoprotection by the microenvironment. Blood. 116:4569–4577. 2010. View Article : Google Scholar : PubMed/NCBI
26	Goswami R, Jabeen R, Yagi R, Pham D, Zhu J, Goenka S and Kaplan MH: STAT6-dependent regulation of Th9 development. J Immunol. 188:968–975. 2012. View Article : Google Scholar : PubMed/NCBI
27	Rozovski U, Calin GA, Setoyama T, D'Abundo L, Harris DM, Li P, Liu Z, Grgurevic S, Ferrajoli A, Faderl S, et al: Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells. Mol Cancer. 12:502013. View Article : Google Scholar : PubMed/NCBI
28	Li P, Grgurevic S, Liu Z, Harris D, Rozovski U, Calin GA, Keating MJ and Estrov Z: Signal transducer and activator of transcription-3 induces microRNA-155 expression in chronic lymphocytic leukemia. PLoS One. 8:e646782013. View Article : Google Scholar : PubMed/NCBI
29	Shaim H, Estrov Z, Harris D, Sanabria Hernandez M, Liu Z, Ruvolo P, Thompson PA, Ferrajoli A, Daher M, Burger J, et al: The CXCR4-STAT3-IL-10 pathway controls the immunoregulatory function of chronic lymphocytic leukemia and is modulated by lenalidomide. Front Immunol. 8:17732018. View Article : Google Scholar : PubMed/NCBI
30	He S, Liao G, Liu Y, Huang L, Kang M and Chen L: Overexpression of STAT3/pSTAT3 was associated with poor prognosis in gastric cancer: A meta-analysis. Int J Clin Exp Med. 8:20014–20023. 2015.PubMed/NCBI
31	Carretero R, Wang E, Rodriguez AI, Reinboth J, Ascierto ML, Engle AM, Liu H, Camacho FM, Marincola FM, Garrido F, et al: Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. Int J Cancer. 131:387–395. 2012. View Article : Google Scholar : PubMed/NCBI
32	Randhawa J, Ostojic A, Vrhovac R, Atallah E and Verstovsek S: Splenomegaly in myelofibrosis - new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors. J Hematol Oncol. 5:432012. View Article : Google Scholar : PubMed/NCBI
33	Mathé E, Nguyen GH, Funamizu N, He P, Moake M, Croce CM and Hussain SP: Inflammation regulates microRNA expression in cooperation with p53 and nitric oxide. Int J Cancer. 131:760–765. 2012. View Article : Google Scholar : PubMed/NCBI